We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blocking a Single Gene Prevents Metastasis of Prostate Cancer in Mouse Model

By LabMedica International staff writers
Posted on 08 Oct 2009
Blocking of a single gene was found to slow the growth of prostate cancer and abolish the establishment of metastases in a mouse model of a hereditary form of the disease.

The transgenic adenocarcinoma mouse-prostate model is characterized by the spontaneous development of prostate cancer with 100% metastasis. More...
Investigators from the University of Michigan (Ann Arbor, USA) worked with this model in their search for a way to slow cancer development that did not rely on vaccination and formation of antibodies.

In a study published in the September 23, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) they reported that targeted mutation of the lymphotoxin alpha (LTA) gene slowed development of primary tumors and almost completely prevented the formation of metastases. LTA mediates a large variety of inflammatory, immunostimulatory, and antiviral responses, and is also involved in the formation of secondary lymphoid organs during development and plays a role in apoptosis. The anticancer effect achieved by blocking LTA formation was apparently due to the rescue of tumor-reactive T cells.

"It appears that the rescued T cells delay tumor formation. It may not be that this approach can prevent cancer altogether, but it can delay the process and slow the aggressive growth and spread of cancer,” explained senior author Dr. Pan Zheng, associate professor of surgery and pathology at the University of Michigan. "There is a certain population with a high likelihood of getting cancer, and we need better strategies to minimize their risk. This approach may be translated into clinical care for those patients.”

Related Links:
University of Michigan



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Thyroid Test
Anti-Thyroid EIA Test
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.